Cytogen filing
Executive Summary
Princeton, New Jersey-based monoclonal antibody R&D firm files a Product License Application for the ovarian cancer diagnostic product OncoScint OV103, an orphan product. The PLA filing is Cytogen's second, following a September 1989 submission for an OncoScint colorectal cancer imaging product.